Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastien J Hotte

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Clinical Biochemistry|April 15, 2014
Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methodsAngela C Rutledge, Gregory R Pond, Sebastien J Hotte, et al.
Heliyon|July 22, 2016
Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancerMatthew P A Henderson, Holger Hirte, Sebastien J Hotte, et al.
Cancer|September 5, 2002
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinomaSebastien J Hotte, Eric W Winquist, Larry Stitt, et al.
Investigational New Drugs|March 30, 2007
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)Jennifer J Knox, Sebastien J Hotte, Christian Kollmannsberger, et al.
Current Oncology (Toronto, Ont.)|March 11, 2021
Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case ReportSuraya Bondy, Camilla Tajzler, Sebastien J Hotte, et al.
Investigational New Drugs|July 20, 2014
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumorsQuincy S Chu, Randeep Sangha, Sebastien J Hotte, et al.
Clinical Biochemistry|April 25, 2009
Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agentPeter A Kavsak, Matthew Henderson, Patricia Moretto, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Investigational New Drugs|December 19, 2017
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancerEvan Y Yu, Susan L Ellard, Sebastien J Hotte, et al.
Acta Oncologica (Stockholm, Sweden)|April 18, 2022
Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic diseaseSherif Ramadan, Kimmen Quan, Kara Schnarr, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Clinical Biochemistry|April 15, 2014
Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methodsAngela C Rutledge, Gregory R Pond, Sebastien J Hotte, et al.
Heliyon|July 22, 2016
Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancerMatthew P A Henderson, Holger Hirte, Sebastien J Hotte, et al.
Cancer|September 5, 2002
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinomaSebastien J Hotte, Eric W Winquist, Larry Stitt, et al.
Investigational New Drugs|March 30, 2007
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)Jennifer J Knox, Sebastien J Hotte, Christian Kollmannsberger, et al.
Current Oncology (Toronto, Ont.)|March 11, 2021
Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case ReportSuraya Bondy, Camilla Tajzler, Sebastien J Hotte, et al.
Investigational New Drugs|July 20, 2014
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumorsQuincy S Chu, Randeep Sangha, Sebastien J Hotte, et al.
Clinical Biochemistry|April 25, 2009
Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agentPeter A Kavsak, Matthew Henderson, Patricia Moretto, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Investigational New Drugs|December 19, 2017
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancerEvan Y Yu, Susan L Ellard, Sebastien J Hotte, et al.
Acta Oncologica (Stockholm, Sweden)|April 18, 2022
Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic diseaseSherif Ramadan, Kimmen Quan, Kara Schnarr, et al.
Pageof 9